This slideshow reviews drug information for Tolsura. This slideshow reviews drug information for Tolsura.
The Food and Drug Administration (FDA) has granted Orphan Drug designation to APX001 (Amplyx Pharmaceuticals) for the treatment of cryptococcosis.
Tolsura, which contains the azole antifungal itraconazole, is formulated using the Company’s proprietary SUBA (SUper-BioAvailable) technology which improves the bioavailability of poorly soluble drugs.
Tolsura is a new formulation of itraconazole, an azole antifungal, that utilizes the Company’s proprietary SUBA (SUper-BioAvailable) technology to improve the bioavailability of poorly soluble drugs.
“This is the first report of decreased insulin requirements in a patient with T1DM correlating with micafungin administration,” noted the authors.
The Phase 3 ReSPECT prophylaxis trial of rezafungin in patients undergoing allogeneic bone marrow transplantation is anticipated to start in the first quarter of 2019.
There was no correlation between the 2016 AUR and either proven infection or necrotizing enterocolitis. However, there was an association between the 2016 regional NICU AUR and surgical volume, mortality rate, and average length of stay
Seven in 10 patients had another condition diagnosed before coccidioidomycosis testing occurred, of whom the vast majority (83%) were prescribed antibacterial medications, 43% were hospitalized, and 29% had culture-positive coccidioidomycosis.
Researchers performed a cross-sectional study that included multiple year pooled data (2003 to 2011) from the National Ambulatory Medical Care Survey (NAMCS) and the National Hospital Ambulatory Medical Care Survey (NHAMCS Outpatient Department).